The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms.
- Authors
- Robinson, J D; Lam, C Y; Minnix, J A; Wetter, D W; Tomlinson, G E; Minna, J D; Chen, T T-L; Cinciripini, P M
- Year
- 2007
- Journal
- The pharmacogenomics journal
- PMID
- 17189962
- DOI
- 10.1038/sj.tpj.6500427
The dopamine receptor D2 (DRD2) gene has polymorphisms that have been linked to regulation of the dopamine system and to an increased prevalence of smoking. The present study examined the relationship of the DRD2 TaqI-A and -B polymorphisms with short-term clinical outcome (abstinence and withdrawal symptoms), collected from daily (14 pre-quit and 42 post-quit) diary data among smokers (n=116) treated with the nicotine patch plus either venlafaxine or placebo. The results showed that B1/B1 or B1/B2 smokers were slightly less likely to be abstinent on a given day than those homozygous for the TaqI-B2 allele. Significant DRD2 TaqI-B x time interactions were found for several of the withdrawal scales, indicating that those smokers with the B1/B1 or B1/B2 genotypes tended to report more symptoms over time compared to those with the B2/B2 genotype. No interactions or main effects were found for the DRD2 TaqI-A polymorphism. The findings demonstrate that smokers homozygous for the TaqI-B2 allele experience progressive improvement in self-reported withdrawal symptoms while smokers with the TaqI-B1 allele showing little change.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Single Nucleotide Polymorphisms Within <i>DRD2, COMT, and DBH</i> and Smoking Cessation: A Systematic Review Considering Genetic Differences by Ancestry and Biological Sex. | Jones SK et al. | — | 2024 | → |
| A scoping review of smoking cessation pharmacogenetic studies to advance future research across racial, ethnic, and ancestral populations. | Prom-Wormley EC et al. | — | 2023 | → |
| Temporal networks of tobacco withdrawal symptoms during smoking cessation treatment. | Lydon-Staley DM et al. | — | 2021 | → |
| Personality Traits or Genetic Determinants-Which Strongly Influences E-Cigarette Users? | Grzywacz A et al. | — | 2020 | → |
| The dopamine D2 receptor mediates approach-avoidance tendencies in smokers. | Zlomuzica A et al. | — | 2018 | → |
| Relationship among methadone dose, polymorphisms of dopamine D2 receptor and tri-dimensional personality questionnaire in heroin-addicted patients. | Huang MW et al. | — | 2016 | → |
| An initial investigation of associations between dopamine-linked genetic variation and smoking motives in African Americans. | Bidwell LC et al. | — | 2015 | → |
| A review of pharmacogenetic studies of substance-related disorders. | Jones JD et al. | — | 2015 | → |
| Effects of Interaction Between Dopamine D2 Receptor and Monoamine Oxidase A Genes on Smoking Status in Young Men. | Huang CL et al. | — | 2015 | → |
| NCAM1-TTC12-ANKK1-DRD2 variants and smoking motives as intermediate phenotypes for nicotine dependence. | Bidwell LC et al. | — | 2015 | → |
| Nicotine withdrawal. | McLaughlin I et al. | — | 2015 | → |
| Suicidal behavior and haplotypes of the dopamine receptor gene (DRD2) and ANKK1 gene polymorphisms in patients with alcohol dependence--preliminary report. | Jasiewicz A et al. | — | 2014 | → |
| The CHRNA3 rs578776 Variant is Associated with an Intrinsic Reward Sensitivity Deficit in Smokers. | Robinson JD et al. | — | 2013 | → |
| Analysis of dopamine D2 receptor (DRD2) gene polymorphisms in cannabinoid addicts. | Nacak M et al. | — | 2012 | → |
| The aggregate effect of dopamine genes on dependence symptoms among cocaine users: cross-validation of a candidate system scoring approach. | Derringer J et al. | — | 2012 | → |
| Pharmacogenetics of antidepressant response. | Porcelli S et al. | — | 2011 | → |
| Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. | Wang J et al. | — | 2010 | → |
| Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. | De Ruyck K et al. | — | 2010 | → |
| Prospective association of dopamine-related polymorphisms with smoking cessation in general care. | Breitling LP et al. | — | 2010 | → |
| The D2 dopamine receptor gene and nicotine dependence among bladder cancer patients and controls. | Clague J et al. | — | 2010 | → |
| Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. | Munafò MR et al. | — | 2009 | → |
| Genetic linkage findings for DSM-IV nicotine withdrawal in two populations. | Pergadia ML et al. | — | 2009 | → |
| Genetics of dopamine receptors and drug addiction: a comprehensive review. | Le Foll B et al. | — | 2009 | → |
| Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. | Quaak M et al. | — | 2009 | → |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | — | 2009 | → |
| Sex heterogeneity in pharmacogenetic smoking cessation clinical trials. | Schnoll RA et al. | — | 2009 | → |
| The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. | Styn MA et al. | — | 2009 | → |
| Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. | Filopanti M et al. | — | 2008 | → |
| Genetic variation in the dopamine pathway and smoking cessation. | David SP et al. | — | 2008 | → |